Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ARIAD Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: Mike McFarland who wrote (573)	6/19/1999 3:50:00 PM
From: Jongmans	Respond to of 4474

Mike, In my view, the osteoporosis program is not a part of the joint venture. The 50/50 is only for new potential products developed within the joint venture. See press-release ARIAD/HMR dd march 6,1997 which states: Operating costs of the joint venture and the right to candidate therapeutic proteins and drug targets will be divided equally between Hoechst Marion Roussel and ARIAD etc: corporate-ir.net For Osteoporosis-collaboration see press-release dd November 7 1995. best regards Martin

To: Mike McFarland who wrote (573)	6/19/1999 10:49:00 PM
From: John Dwyer	Read Replies (2) \| Respond to of 4474

Hi Mike, I wasn't clear where you were headed with this idea but if you are looking for a cancer link with the SH3 domain and sos, check out Sugen's pipeline (grb2 inhibs). Ariad was working on grb2 as well but Sugen's patent that issued a couple years ago took the wind out of Ariad's cancer program. With regard to the reports from SmallCaps, it's real nice to see some fresh coverage on these smallcap biotechs. I realize that the bulge-bracket investment banks can't afford to cover such smallfry but there is a critical need for this type of analysis. John